Early but not serial ustekinumab concentration measurements are associated with clinical outcomes in Crohn's disease and ulcerative colitis: the Stockholm Ustekinumab study (STOCUSTE). (PubMed, Eur J Gastroenterol Hepatol) - Sep 22, 2026 - "In this study, an early (≤3 months) UST concentration was associated with remission, whereas concentrations measured at later time points did not differ between remission and nonremission. In this real-world cohort serial monitoring beyond 3 months showed poor correlation with clinical outcomes."
Clinical data • Journal • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis • IL12A
|
|
Alexandra Borin; Charlotte Höög; Charlotte Söderman; Christina Wennerström; Francesca Bello; Fredrik Johansson; Haider Sabhan; Mikael Lördal; Ole Forsberg; Samer Muhsen; Sven Almer
|